echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Genentech reaches nearly $700 million to develop stem cell therapy for common blinding eye disease

    Genentech reaches nearly $700 million to develop stem cell therapy for common blinding eye disease

    • Last Update: 2022-02-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Lineage Cell Therapeutics announced today that it has entered into an exclusive global collaboration and license agreement with Genentech, a Roche company, to develop and commercialize OpRegen, a retinal pigment epithelial (RPE)-based cell replacement therapy.


    AMD is the leading cause of vision loss in people over the age of 60, with dry AMD accounting for 85-90%


    Under the terms of the collaboration agreement, Lineage will complete activities related to ongoing clinical trials and be responsible for certain manufacturing activities


    References:

    [1] Lineage Establishes Exclusive Worldwide Collaboration With Genentech For The Development And Commercialization Of Opregen® Rpe Cell Therapy For The Treatment Of Ocular Disorders.


    (Original abridged)

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.